UCB

Dr Reddy's Lab completes acquisition of UCB's select brands

Dr Reddy's has said the acquired UCB portfolio would accelerate its presence in the high growth areas of dermatology, respiratory and pediatrics, with market leading brands such as Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M.

Dr Reddy's sees India sales growing 20% on new product launches

Dr Reddy`s Laboratories Ltd, India`s second-largest drugmaker, expects domestic sales to grow nearly 20 percent this financial year, helped by the launch of nearly two dozen products, a senior executive said.

Dr Reddy's to buy UCB's select brands for Rs 800 crore

"The acquired business is being sold on a slump sale basis. The revenues of the acquired business is approximately Rs 150 crore for the calendar year 2014," it added.

In bright summer, try black and white fashion

Apparel brands and designers have launched lines in bright and bold colours for this season.